A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study

M. S. Soloway, A. Einstein, M. P. Corder, W. Bonney, G. R. Prout, J. Coombs

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.

Original languageEnglish
Pages (from-to)767-772
Number of pages6
JournalCancer
Volume52
Issue number5
StatePublished - Oct 6 1983
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Cyclophosphamide
Cisplatin
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. / Soloway, M. S.; Einstein, A.; Corder, M. P.; Bonney, W.; Prout, G. R.; Coombs, J.

In: Cancer, Vol. 52, No. 5, 06.10.1983, p. 767-772.

Research output: Contribution to journalArticle

Soloway, M. S. ; Einstein, A. ; Corder, M. P. ; Bonney, W. ; Prout, G. R. ; Coombs, J. / A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study. In: Cancer. 1983 ; Vol. 52, No. 5. pp. 767-772.
@article{aed7b924a3464c3495b18e91ab65e055,
title = "A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study",
abstract = "A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20{\%}), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9{\%}), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.",
author = "Soloway, {M. S.} and A. Einstein and Corder, {M. P.} and W. Bonney and Prout, {G. R.} and J. Coombs",
year = "1983",
month = "10",
day = "6",
language = "English",
volume = "52",
pages = "767--772",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group A study

AU - Soloway, M. S.

AU - Einstein, A.

AU - Corder, M. P.

AU - Bonney, W.

AU - Prout, G. R.

AU - Coombs, J.

PY - 1983/10/6

Y1 - 1983/10/6

N2 - A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.

AB - A prospective multi-institutional randomized trial compared the use of cisplatin (DDP) alone to the combination of DDP and cyclophosphamide in patients with advanced urothelial cancer. Patients were stratified according to measurable or evaluable tumor and performance status. The dose of DDP was 70 mg/m2 and the initial dose of cyclophosphamide was 750 mg/m2. There were 10 objective responders (20%), including 5 complete responders, among the 50 evaluable patients who received DDP alone, and 7 responders (11.9%), 3 complete, among the 59 receiving the combination therapy. Approximately one third of the patients in each treatment arm were stable at the 9-week evaluation. There was no statistical significance between the response rates in the two treatment arms.

UR - http://www.scopus.com/inward/record.url?scp=0020605706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020605706&partnerID=8YFLogxK

M3 - Article

C2 - 6347356

AN - SCOPUS:0020605706

VL - 52

SP - 767

EP - 772

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -